Rheumatoid arthritis (RA) is treated with medications that slow or stop the immune system from attacking your joints, not just drugs that mask pain. The cornerstone of modern treatment is a class of medications called disease-modifying antirheumatic drugs (DMARDs), which can prevent permanent joint damage when started early. Most people with RA will use one or more DMARDs, sometimes combined with short-term steroids, physical activity, and in advanced cases, surgery.
Conventional DMARDs: The First Line of Defense
Methotrexate is the most widely prescribed first-line treatment for RA. It’s taken once a week, typically starting at a low dose that your doctor adjusts upward based on your response. Methotrexate works by dialing down the overactive immune cells that drive joint inflammation. It doesn’t work overnight. Most people notice improvement within 4 to 8 weeks, and it can take several months to reach full effect.
The most common side effect is nausea, which affects anywhere from 20% to 70% of patients in the first year. Some people experience what’s called “methotrexate flu,” a day or two of low-grade fever, muscle aches, and chills after their weekly dose. Mouth sores occur in up to a third of patients. More serious but rarer problems include liver enzyme elevations (about 22% of patients see mild increases) and, very uncommonly, blood cell count drops or lung inflammation. Taking folic acid alongside methotrexate helps reduce many of these side effects.
If methotrexate isn’t enough on its own or isn’t tolerated well, other conventional DMARDs can be added or substituted. Leflunomide is taken daily and works through a different pathway to suppress immune activity. Its most limiting side effect is diarrhea, and it can also raise blood pressure and cholesterol. Sulfasalazine and hydroxychloroquine are two other options, often used in combination with methotrexate for a more aggressive approach.
Biologic DMARDs: Targeting Specific Immune Signals
When conventional DMARDs don’t bring your disease under adequate control, biologics are the next step. These are lab-engineered proteins, given by injection or infusion, that block specific molecules driving inflammation in your joints.
The largest and longest-studied group are TNF inhibitors. TNF is a signaling molecule produced by immune cells that triggers much of the joint destruction in RA. It stimulates the cells lining your joints to release enzymes that break down cartilage and bone. TNF inhibitors intercept this signal before it can do damage. Several are available, including infliximab (given by IV infusion), adalimumab and etanercept (both self-injected at home). They differ in how they’re delivered and how often you take them, but they all target the same inflammatory pathway.
Other biologics go after different parts of the immune cascade. Some block interleukin-6, another inflammatory signaling molecule. Others target specific immune cells called B cells or T cells. Your rheumatologist chooses among these based on your disease profile, other health conditions, and how you’ve responded to previous treatments. If one biologic doesn’t work, switching to another class often does.
JAK Inhibitors: A Newer Oral Option
JAK inhibitors are pills that block a group of enzymes inside immune cells, interrupting the signals that tell those cells to ramp up inflammation. For many patients, the appeal is convenience: a daily tablet instead of injections or infusions.
However, the FDA has placed its strongest safety warning on these medications. A large clinical trial revealed increased risks of serious heart-related events, certain cancers, blood clots, and death compared to TNF inhibitors. As a result, JAK inhibitors are now reserved for patients who haven’t responded to or can’t tolerate at least one TNF inhibitor. If you have cardiovascular risk factors, a history of smoking, or a past malignancy, your doctor will weigh these risks carefully before prescribing one.
Steroids as Short-Term Bridge Therapy
Corticosteroids like prednisone can dramatically reduce inflammation within days, which makes them useful for controlling symptoms while you wait for a DMARD to kick in. This is called bridge therapy. The guiding principle is straightforward: use as much as necessary, but as little as possible.
Current guidelines from EULAR, the European rheumatology organization, recommend tapering and stopping steroids as quickly as possible once your DMARD takes effect. Long-term steroid use, even at low doses, carries real consequences: bone thinning, weight gain, elevated blood sugar, increased infection risk, and skin fragility. Steroids are a powerful tool for getting through the early weeks of treatment or managing a flare, but they are not meant to be a permanent solution.
What Remission Looks Like
The goal of treatment is remission, or at least low disease activity, meaning minimal pain, little or no swelling, and normal daily function. Not everyone reaches full remission, but modern treatments have made it a realistic target for many people. Among patients starting their first biologic, roughly 25% to 45% achieve meaningful remission benchmarks within six months, depending on which measure is used. Results tend to be better when treatment starts early in the disease course, and response rates drop with each successive medication switch, which is one reason rheumatologists push for aggressive treatment upfront.
Blood Test Monitoring During Treatment
DMARDs suppress parts of your immune system, and some can affect your liver, kidneys, or blood cell counts. Regular lab work is essential to catch problems early. On methotrexate, you’ll typically have blood drawn monthly for the first six months, checking your blood cell counts, liver enzymes, and kidney function. After that, testing moves to every two months if everything looks stable.
Leflunomide follows a similar schedule: monthly liver and blood count checks for the first six months, then every six to eight weeks. If you’re on both methotrexate and leflunomide, monthly monitoring continues indefinitely because the combination increases the chance of liver enzyme elevations. Sulfasalazine requires monthly labs for the first three months, then every three months. These blood draws are a routine part of living with RA treatment, and they’re how your care team ensures your medication stays safe over the long term.
Exercise and Physical Therapy
Physical activity is not just safe for people with RA, it’s one of the most effective things you can do alongside medication. European rheumatology guidelines recommend that people with inflammatory arthritis follow the same exercise targets as the general population: at least 150 minutes per week of moderate aerobic activity, plus muscle-strengthening exercises on two or more days per week.
Research across multiple clinical trials shows that cardiovascular exercise produces a moderate improvement in aerobic fitness, and strength training produces a moderate improvement in muscle strength, both without worsening joint damage. Stronger muscles around affected joints absorb more of the mechanical load, which reduces pain and protects cartilage. A physical therapist can design a program that works around your most affected joints, especially during flares when you may need to modify intensity. Swimming, cycling, and walking are particularly joint-friendly options.
When Surgery Becomes an Option
Joint replacement is considered only after non-surgical treatments have had a reasonable chance to work and have fallen short. It’s typically reserved for advanced, end-stage joint disease where cartilage is largely gone and the joint causes disabling pain or significant loss of function. The knees, hips, and shoulders are the most commonly replaced joints in RA.
The decision depends on two things: how much the damaged joint is affecting your quality of life, and whether you’re medically fit for surgery. With modern DMARDs and biologics, fewer people with RA need joint replacement than in previous decades, but it remains a reliable option for restoring mobility and eliminating pain when a joint is beyond what medication can repair.